-
Product Insights
NewNet Present Value Model: Cardiff Oncology Inc’s Onvansertib Fumarate
Empower your strategies with our Net Present Value Model: Cardiff Oncology Inc's Onvansertib Fumarate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Diffuse Large B-Cell Lymphoma Drug Details: Nemtabrutinib (ARQ-531)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onvansertib Fumarate in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onvansertib Fumarate in Triple-Negative Breast Cancer (TNBC) Drug...
-
Product Insights
Chronic Myelomonocytic Leukemia (CMML) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Myelomonocytic Leukemia (CMML) - Drugs In Development, 2023’, provides an overview of the Chronic Myelomonocytic Leukemia (CMML) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Myelomonocytic Leukemia (CMML), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Medulloblastoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Medulloblastoma - Drugs In Development, 2023’, provides an overview of the Medulloblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Brain Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Brain Cancer - Drugs In Development, 2023’, provides an overview of the Brain Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Acquired Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies
Acquired Gene or Chromosome Alterations Pipeline Market Report Overview Acquired Gene or Chromosome Alterations are reagents employed for genetic testing to detect cancer-causing or related alterations. The Acquired Gene or Chromosome Alterations pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated...